Anti-inflammatory Properties
Properties of AKBA
BosPure
Specification of BosPure
Mechanism Proposed for AKBA
Comparison of BosPure vs Other Boswellia Serrata Extracts
Clinical Studies on BosPure
 

BosPure®

Commercial extracts are sold on the basis of titratable acid content, but the actual boswellic acids as estimated by HPLC would be much less. These extracts contain at least 6 boswellic acids with the most active constituent, AKBA being present to the least amount, typically 1 – 3%. In comparison BosPure®; contains only 3 boswellic acids (we call them the active core of Boswellia Serrata) with AKBA content enriched four-fold. β-boswellic acid, which is the major component of commercial extracts, is ABSENT in BosPure®.

The active constituents are three acetyl boswellic acid, namely, Acetyl-α-Boswellic Acid, Acetyl-β-Boswellic Acid, and Acetyl-11-keto-β-Boswellic Acid (AKBA). Other boswellic acids are either without biological activity, or in some cases have negative or detrimental activities.


Acetyl-a-Boswellic Acid Acetyl--Boswellic Acid
   
Acetyl-11-Keto--Boswellic Acid

WHY NO β-BOSWELLIC ACID

According to Safayhi et al1, at low concentrations of active constituents, Boswellia Serrata extract actually promoted 5-lipoxygenase product formation, rather than suppression in an in vitro study. In other words, with products containing very low contents of AKBA, the result would be increased production of leukotrienes, just the opposite of what was intended! They further state: “The in vitro data underline the major importance of drug standardization when Boswellia resin containing preparations are used for the treatment of diseases”. The take-home message is that you simply need more AKBA in your product. 1-2% AKBA just won’t do.

Further, according to a recent paper appearing in the British Journal of Pharmacology2, in an ex vivo model, β-boswellic acid, mobilized Ca2+ from internal stores, strongly stimulated the platelet-induced generation of thrombin in an ex-vivo model, the liberation of Arachidonic acid, and induces platelet aggregation in a Ca2+ dependent manner. In contrast, AKBA or KBA did not cause aggregation or generation of thrombin. In other words, β-boswellic acid, the major component of commercial Boswellia Serrata extracts could precipitate coronary thrombosis in vulnerable patients. Furthermore, the increased calcium flux can activate the generation of Arachidonic acid as well as activate 5-lipoxygenase and perpetuate the leukotrienes cascade of inflammation, rather than inhibit it, an effect opposite of what was intended.

Significantly, BosPure® does not contain β-boswellic acid.

1. Safayhi H, Boden SE, Schweizer S, Ammon HP, Concentration-dependent potentiating and inhibitory effects of Boswellia extracts on 5-lipoxygenase product formation in stimulated PMNL, Planta Med. 2000, 66(2):110-3.
2. Poeckel D, Tausch L, Altmann K, et al. Induction of central signalling pathways and select functional effects in human platelets by beta-boswellic acid, Br. J. Pharmacol., 2005, 146:514-26

 
A joint venture with Arjuna Natural Extracts Ltd

* The contents on this website have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational
purposes only. You should consult with a healthcare professional before starting any diet, exercise or supplementation program.
All Contents Copyright © 2008. Dolcas Biotech All Rights Reserved Website Developed by Cedar Solutions